Orchestra BioMed (OBIO) - 2025 Q4 - Annual Report

Financial Performance and Challenges - Orchestra BioMed Holdings, Inc. has a history of net losses and expects to continue incurring losses for the foreseeable future[17]. - The company anticipates challenges in raising capital in the future, which could adversely affect its business and financial condition[17]. - The market sizes for the company's product candidates may be smaller than estimated, impacting future revenue projections[17]. - The company may need to raise capital in the future, and failure to do so could harm its financial condition and operating results[17]. Regulatory and Compliance Issues - The clinical study process for regulatory approvals is lengthy and expensive, with uncertain outcomes that could harm the business if studies are unsuccessful or delayed[17]. - The company anticipates difficulties in obtaining regulatory approvals for international sales expansion, even if products are certified[17]. - The company may face challenges in maintaining compliance with regulatory requirements, which could lead to enforcement actions and penalties[19]. - Regulatory scrutiny and post-marketing requirements will continue to apply to the company's products even after receiving approvals[19]. Dependence on Partnerships and Third Parties - Orchestra BioMed is highly dependent on partners for the successful marketing and sale of its initial product candidates, with no assurance of successful partnerships[17]. - The company is highly dependent on partners and third-party vendors for manufacturing and marketing its product candidates, with no assurance of successful partnerships[18]. - The company relies on third parties for manufacturing and supply chain management, which poses risks if not properly managed[18]. - The company relies on third parties for critical components and materials, with no redundancy in the supply chain[18]. Market and Demand Risks - Healthcare cost-containment pressures could decrease demand for the company's products and negatively impact pricing and procedure volumes[19]. - Healthcare cost-containment pressures could decrease demand for the company's products and affect pricing and procedure volumes[19]. Manufacturing and Development Limitations - The company has limited pharmaceutical manufacturing experience, which may lead to development or manufacturing problems that could limit revenue growth[19]. - The clinical study process for regulatory approvals is lengthy, expensive, and carries substantial risks, which could harm the business if studies are unsuccessful or delayed[17]. - The company may not effectively protect its intellectual property, which could adversely affect its business and financial condition[19].